Skip to main content
Clinical Trials/NCT07213505
NCT07213505CompletedNot Applicable

Investigating New Front-end Features in the SONNET 3

MED-EL Elektromedizinische Geräte GesmbH2 sites in 1 country40 target enrollmentStarted: September 29, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
40
Locations
2
Primary Endpoint
Oldenburg Sentence Test in noise (S0 N±135)

Study Overview

Brief Summary

Cochlear implants help individuals with hearing loss by delivering electrical signals directly to the auditory nerve, bypassing damaged parts of the ear. While they significantly improve speech perception in quiet environments and over the telephone, challenges remain in noisy environments due to interference from background noise. To address this, advancements in signal-processing strategies, microphone technology, and noise-reduction algorithms have been introduced.

The focus of the study is on two new front-end features:

  • Focused Beamformer - Enhances directional hearing.
  • AI Mode Medium - Utilizes the adaptive intelligence for optimized sound processing.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Minimum age of eighteen (18) years at time of enrolment
  • •Experienced MED-EL cochlear implant (CI) user (≥ 6 months) for the ear to be tested
  • •User of a MED-EL Audio Processor (i.e. a SONNET, SONNET 2, SONNET 3, or RONDO 3 ≥ 3months)
  • •Post-lingual onset of severe to profound sensory-neural hearing loss on the ear to be tested
  • •A minimum of 40% speech recognition in the Freiburg Monosyllables Test in quiet at 65 dB sound pressure level (SPL) for the ear to be tested (at the last time tested in clinical routine)
  • •Signed and dated Informed Consent Form (ICF) before the start of any study-specific procedure.

Exclusion Criteria

  • •Lack of compliance with any inclusion criteria
  • •CI user with contralateral hearing equal to or better than 30 dB (pure-tone average over the following frequencies: 250, 500, 1000, and 2000 Hz)
  • •Implanted with C40X, or C40C on the ear to be tested
  • •Implanted with an auditory brainstem implant (ABI) or Split electrode array
  • •Known allergic reactions to components of the investigational medical device
  • •Anything that, in the opinion of the Investigator, would
  • •place the subject at increased risk
  • •preclude the subject's full compliance with or completion of the study

Arms & Interventions

Adult MED-EL Cochlear implant users with post-lingual, severe to profound sensory-neural hearing los

Experimental

Testing new versus approved front-end features (within subject design)

Intervention: Testing new front-end features (Other)

Outcomes

Primary Outcomes

Oldenburg Sentence Test in noise (S0 N±135)

Time Frame: immediately after the intervention

Speech perception in noise measured in dB SNR (the new Focused beamformer and the Omnidirectional setting are tested)

Secondary Outcomes

  • Oldenburg Sentence Test in noise (S0 N±135)(immediately after the intervention)

Investigators

Sponsor
MED-EL Elektromedizinische Geräte GesmbH
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials